Jay Keasling

Jay Keasling is a pioneering American scientist and entrepreneur whose work has fundamentally advanced the fields of synthetic biology and metabolic engineering. He is best known for leading the development of a microbial production platform for the lifesaving antimalarial drug artemisinin, a breakthrough that demonstrated the potential of engineered biology to address global health challenges. As a professor at the University of California, Berkeley and a senior scientist at the Lawrence Berkeley National Laboratory, he has played a central role in establishing the foundational tools and principles of the modern synthetic biology industry. His research and leadership at institutions like the Joint BioEnergy Institute continue to drive innovation in biofuels and biomanufacturing.

Early life and education

Born in Nebraska, he developed an early interest in science and engineering. He pursued his undergraduate education at the University of Nebraska–Lincoln, where he earned a Bachelor of Science degree in Chemical Engineering. For his graduate studies, he attended the University of Michigan, completing his Ph.D. in Chemical Engineering under the mentorship of James E. Bailey, a prominent figure in the field of biochemical engineering. This foundational training in engineering principles applied to biological systems set the stage for his future groundbreaking work at the intersection of biology and engineering.

Career and research

Following his doctoral work, he began his academic career as a professor at the University of California, Berkeley, with a joint appointment at the Lawrence Berkeley National Laboratory. His early research focused on manipulating the metabolic pathways of microorganisms like Escherichia coli and Saccharomyces cerevisiae to produce valuable chemicals. He co-founded the company Amyris to commercialize technologies derived from his laboratory's research. He has also served as the Chief Executive Officer of the Joint BioEnergy Institute, a U.S. Department of Energy Bioenergy Research Center dedicated to developing advanced biofuels. His work has been instrumental in creating standardized biological parts, such as the BioBrick assembly standard, which are critical for the field of synthetic biology.

Synthetic biology and artemisinin

His most celebrated achievement is the engineering of a strain of Saccharomyces cerevisiae to produce high yields of artemisinic acid, the precursor to the antimalarial drug artemisinin. This project, conducted in collaboration with the Institute for OneWorld Health and funded in part by the Bill & Melinda Gates Foundation, aimed to create a stable, scalable, and cost-effective supply of the drug, which is traditionally extracted from the plant Artemisia annua. The successful development and subsequent licensing of this technology to the pharmaceutical company Sanofi marked the first large-scale industrial application of synthetic biology for a pharmaceutical product, providing a new manufacturing route for a critical global health commodity.

Awards and honors

His contributions have been recognized with numerous prestigious awards and memberships in elite scientific societies. He is a recipient of the Heinz Award for Technology, the Economy and Employment, and the Biotechnology Heritage Award. He has been elected to both the National Academy of Engineering and the National Academy of Sciences, among the highest honors for an American engineer and scientist. Other notable recognitions include the Eni Award, the International Metabolic Engineering Award, and being named a fellow of the American Association for the Advancement of Science. He has also received the Presidential Green Chemistry Challenge Award for his work on artemisinin.

Personal life

He maintains a relatively private personal life while being a prominent figure in the scientific community. He is known to be an avid advocate for the ethical development and application of synthetic biology technologies. His commitment to using science for public good is evident in his leadership on projects like the artemisinin initiative, which prioritized accessibility and impact in developing countries over purely commercial interests. He continues to mentor numerous students and postdoctoral researchers at the University of California, Berkeley, shaping the next generation of leaders in bioengineering.

Category:American chemical engineers Category:Synthetic biologists Category:University of California, Berkeley faculty Category:Members of the United States National Academy of Sciences Category:Members of the United States National Academy of Engineering